The Electrospinning Company is a partner in the EU funded H2020 Research and Innovation action BIORIMA (Biomaterial Risk Management). The project aims to develop an integrated risk management framework for nano-biomaterials used in advanced therapeutic medicinal products and medical devices. The BIORIMA risk management framework is a structure upon which the validated tools and methods for materials, exposure, hazard and risk identification/assessment and management are allocated plus a rationale for selecting and using them to manage and reduce the risk for specific nano-biomaterials used in medical applications.
Specifically, the IRM framework will consist of:
(i) Risk Management strategies and systems, based on validated methodologies, tools, and guidance, for monitoring and reducing the risks together with methods for evaluating them;
(ii) Validated methodologies and tools to identify the potential exposure and hazard posed by nano-biomaterials to humans and the environment;
(iii) A strategy for intelligent testing and tiered risk assessment for nano-biomaterials used in medical applications.
(ii) Validated methodologies and tools to identify the potential exposure and hazard posed by nano-biomaterials to humans and the environment;
(iii) A strategy for intelligent testing and tiered risk assessment for nano-biomaterials used in medical applications.
BIORIMA has a runtime of 4 years, with 41 consortium partners and a project budget of almost 8.000.000 €. The Electrospinning Company will manufacture a range of nano-biomaterials to be used as standards for method and systems development. Dr Brendan Robb is our lead contact.
The official Kick-off-Meeting will be held in Paris from 19th to 21st February 2018.
Leave a Reply
You must be logged in to post a comment.